Trial Profile
A Phase 1 Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Compared to Placebo in HSV-2 Seropositive Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2016
Price :
$35
*
At a glance
- Drugs Herpes simplex vaccine (Primary) ; QS 21
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Adverse reactions
- 28 Jun 2011 Results were presented at the BIO International Convention.
- 27 Jul 2010 Top-line results reported in an Antigenics media release. Data also presented at the annual meeting of the International Herpes Workshop.
- 26 Oct 2008 Added actual number of patients, based on information from ClinicalTrials.gov.